{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-277889","form_type":"8-K","ticker":null,"cik":"0001780097","company_name":"Baudax Bio, Inc.","filed_at":"2023-11-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.395745+00:00","generated_at":"2026-06-08T02:38:31.318283+00:00","sec_items":["3.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Baudax Bio receives Nasdaq delisting notice; suspension Nov 16","bullets":["Nasdaq Panel determined to delist BXRX common stock for failure to meet initial listing requirements by Nov 13, 2023.","Trading suspension on Nasdaq Capital Market effective at opening on November 16, 2023.","Company has 15 days to request a review by the Nasdaq Listing and Hearing Review Council.","If no timely request, Form 25-NSE will be filed removing securities from Nasdaq registration.","Stock may become eligible for OTC trading, but no assurance is given."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-277889","json":"https://secwatch.observer/filing/0001193125-23-277889.json","markdown":"https://secwatch.observer/filing/0001193125-23-277889.md","text":"https://secwatch.observer/filing/0001193125-23-277889.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1780097/000119312523277889/0001193125-23-277889-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1780097/000119312523277889/d850440d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T02:38:31.318283+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"86a752eb4c8f60843810f194ee4406e331f1d471","claim":"Baudax Bio, Inc. received a nasdaq delisting notice notice regarding other (rules 5550(b)(1), 5550(a)(2)).","evidence_excerpt":"November 14, 2023, the Company received a determination letter (the “Delisting Notification”) from the Nasdaq Hearings Advisor stating that the Panel has determined to delist the Company’s common stock, par value $0.01 per share (the “Common Stock”) from the Nasdaq Capital Market, and Nasdaq will accordingly suspend trading in the Company’s Common Stock, effective at the opening of trading on November 16, 2023, because the Company did not demonstrate compliance initial listing requirements by November 13, 2023. Pursuant to the Delisting Notification, the Company has a period of 15 days from th","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1780097/000119312523277889/0001193125-23-277889-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"delisting notice"},{"label":"Rules","value":"5550(b)(1), 5550(a)(2)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}